MOLECULAR MODELING OF 5-HT3 RECEPTOR LIGANDS

被引:31
作者
EVANS, SM [1 ]
GALDES, A [1 ]
GALL, M [1 ]
机构
[1] BOC HEALTHCARE INC, ANAQUEST INC, MURRAY HILL, NJ 07974 USA
关键词
MOLECULAR MODELING; 5-HT3; RECEPTOR; SEROTONIN; PHARMACOPHORE; STRUCTURE-ACTIVITY RELATIONSHIPS; 3-DIMENSIONAL; ANTIEMETIC;
D O I
10.1016/0091-3057(91)90123-J
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
Ligands of various chemical classes (e.g., indoles, indazoles, benzamides, carbazoles, and quinolines) have demonstrated high affinity for the 5-HT3 receptor in radiolabeled ligand-binding studies, and have shown 5-HT3 receptor antagonistic activity in functional assays which utilize the excitatory effects of 5-HT on enteric neurons and autonomic afferents. Several 5-HT3 antagonists are currently being evaluated for potential use in the treatment of migraine, schizophrenia, and anxiety, and a few have already demonstrated high efficacy as antiemetics in cancer chemotherapy. The purpose of this presentation is to highlight the significant structure-affinity relationships (SAFIR) and common geometrical features among 5-HT3 receptor ligands, and to describe the three-dimensional pharmacophore for the 5-HT3 recognition site derived from computational techniques. The chemical template containing the recognition elements (functional groups) for the 5-HT3 receptor are: an aromatic or heteroaromatic ring system, a coplanar carbonyl group, and a nitrogen center, interrelated by well-defined distances. Two "binding shapes" or "active shapes" for 5-HT3 ligands have been identified from detailed conformational analyses.
引用
收藏
页码:1033 / 1040
页数:8
相关论文
共 68 条
  • [21] GIDDA JS, 1990, DIGESTIVE DISEA 0513
  • [22] SEROTONIN RECEPTORS AND THEIR LIGANDS - A LACK OF SELECTIVE AGENTS
    GLENNON, RA
    DUKAT, M
    [J]. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1991, 40 (04) : 1009 - 1017
  • [23] BINDING OF ARYLPIPERAZINES TO 5-HT3 SEROTONIN RECEPTORS - RESULTS OF A STRUCTURE-AFFINITY STUDY
    GLENNON, RA
    ISMAIEL, AEM
    MCCARTHY, BG
    PEROUTKA, SJ
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1989, 168 (03) : 387 - 392
  • [24] GORDON JC, 1989, J PHARMACOL EXP THER, V251, P962
  • [25] DETERMINATION OF THE MOLECULAR-SIZE OF THE 5-HT3 RECEPTOR-BINDING SITE BY RADIATION INACTIVATION
    GOZLAN, H
    SCHECHTER, LE
    BOLANOS, F
    EMERIT, MB
    MIQUEL, MC
    NIELSEN, M
    HAMON, M
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY-MOLECULAR PHARMACOLOGY SECTION, 1989, 172 (06): : 497 - 500
  • [26] GUSLANDI M, 1989, Drugs of Today, V25, P101
  • [27] DIFFERENTIAL INTERACTIONS OF TRADITIONAL AND NOVEL ANTIEMETICS WITH DOPAMINE-D2 AND 5-HYDROXYTRYPTAMINE-3 RECEPTORS
    HAMIK, A
    PEROUTKA, SJ
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1989, 24 (05) : 307 - 310
  • [28] CONFORMATION-ACTIVITY RELATIONSHIP STUDY OF 5-HT3 RECEPTOR ANTAGONISTS AND A DEFINITION OF A MODEL FOR THIS RECEPTOR-SITE
    HIBERT, MF
    HOFFMANN, R
    MILLER, RC
    CARR, AA
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1990, 33 (06) : 1594 - 1600
  • [29] IDENTIFICATION OF SEROTONIN 5-HT3 RECOGNITION SITES BY RADIOLIGAND BINDING IN NG108-15 NEUROBLASTOMA-GLIOMA CELLS
    HOYER, D
    NEIJT, HC
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1987, 143 (02) : 291 - 292
  • [30] HOYER D, 1988, MOL PHARMACOL, V33, P303